Benefits beyond weight loss Liraglutide, semaglutide (2.4 mg weekly dose) and tirzepatide lower blood pressure, improve lipid profiles, reduce blood glucose levels, reduce C-reactive protein levels and improve physical functioning
FFAR1 is expressed in the pancreatic -cell, where evidence suggests it can influence glucose-stimulated insulin release (197)
& Hirst, J
Wegovy offers the assurance of a brand-name, FDA-approved product, while compounded semaglutide offers a flexible and available alternative for those facing shortages or requiring personalized dosing
doi: 10.3389/FMED.2021.672370/BIBTEX Summary Keywords myalgic encephalomyelitis, long COVID, post-COVID-19 vaccine syndrome, ASIA syndrome, EBV, SARS-CoV-2, HLA-II, hypophysitis Citation Ruiz-Pablos M, Paiva B and Zabaleta A (2024) Hypocortisolemic ASIA: a vaccine- and chronic infection-induced syndrome behind the origin of long COVID and myalgic encephalomyelitis
Schedule: Weeks 1-4: 2mg weekly Week 5+: 4mg weekly (maintenance) This protocol reaches maintenance by week 5 and provides clinically meaningful weight loss with the mildest side effect profile
